Please login to the form below

Not currently logged in
Email:
Password:

Novacyt launches diagnostic test to differentiate between COVID-19 and flu

Test launches in time for upcoming winter flu season

Biotech company Novacyt has announced the launch of a new diagnostic test which can tell the difference between COVID-19 and the flu, as the winter flu season approaches.

The clinical diagnostics company said that its Winterplex test includes two gene targets specific to COVID-19, as well as gene targets for influenza A and B and respiratory syncytial virus (RSV).

According to the company, clinical trial data of the test demonstrated 100% specificity and between 96% and 100% sensitivity across the panel.

The new polymerase chain reaction (PCR) respiratory test can be used on any open PCR platform, including Novacyt’s portable q32 instrument.

PCR tests are the most preferred form of diagnostics for COVID-19, as they can be used to directly detect the presence of an antigen in the body, as opposed to just the presence of antibodies.

This is a more accurate way of distinguishing whether or not an individual has the disease, as the PCR test can detect viral RNA which will be present in the body before antibodies form. This means that PCR tests can tell whether someone has the virus soon after they catch it.

“Novacyt has established itself as a pioneer in COVID-19 diagnostics through the rapid development and success of its COVID-19 PCR test and the launch of Winterplex is another example of this innovative approach,” said Graham Mullis, group chief executive officer of Novacyt.

"We believe Winterplex is one of the world’s first approved respiratory test panels that can differentiate between COVID-19 and other common respiratory diseases. The test panel is a key addition to our COVID-19 product portfolio to support healthcare providers as we approach flu season in the Northern hemisphere,” he added.

Novacyt’s COVID-19 PCR test has seen increasing demand since its launch earlier this year, with sales in June hitting €25.4m (£22.5m).

The company expects its new Winterplex test, combined with continued growth of its existing COVID-19 PCR test, to continue to drive growth well into next year.

"The immediate pipeline of new products is expected to drive incremental revenue for the Company in the near-term, but Novacyt’s strengthened financial position also means we are able to redefine our R&D pipeline for the next three years, which we expect to drive significant and continued growth opportunities in the longer-term,” added Mullis.

Article by
Lucy Parsons

28th August 2020

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....
Top 10 ways that Medical Affairs teams can leverage the Impetus InSite Platform®
Some of the most popular and innovative ways of using our cutting-edge asynchronous and synchronous virtual tools for Medical Affairs teams....